Oruka Therapeutics, Inc. ORKA
Closing"), we completed our acquisition (the "Merger") of Oruka Therapeutics, Inc. ("Pre-Merger Oruka")
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the "Merger Agreement"). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA biopharma, Inc. ("ARCA") and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC ("Second
Last close
80.15
2026-10-23
Market cap
$5.31B
2026-06-30 share count
52-week range
25.23 - 115.52
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $100.6M | — | $1.0M | $4.7M | $13.8M | $5.0M | $1.8M | $4.2M | $14.1M | $12.3M |
| SG&A | $21.4M | — | $6.3M | $5.8M | $5.5M | $4.8M | $4.0M | $3.9M | $4.6M | $4.3M |
| Total operating expenses | $122.1M | — | $7.3M | $10.6M | $19.3M | $9.8M | $5.8M | $8.1M | $18.7M | $16.6M |
| Operating income | -$122.1M | — | -$7.3M | -$10.6M | -$19.3M | -$9.8M | -$5.8M | -$8.1M | -$18.7M | -$16.6M |
| Interest expense | — | — | — | — | — | $9.0K | $7.0K | $8.0K | $6.0K | — |
| Pre-tax income | -$105.4M | — | -$5.3M | -$9.9M | -$19.3M | -$9.7M | -$5.6M | -$8.0M | -$18.6M | -$16.4M |
| Income tax | — | — | $0 | $0 | $0 | $9.0K | $167.0K | $31.0K | $61.0K | $0 |
| Net income | -$105.4M | -$83.7M | -$5.3M | -$9.9M | -$19.3M | -$9.7M | -$5.5M | -$7.9M | -$18.5M | -$16.4M |
| EPS, basic | — | — | -0.37 | -0.69 | -1.39 | — | — | — | — | — |
| EPS, diluted | — | — | -0.37 | -0.69 | -1.39 | -2.07 | -4.15 | -10.31 | -1.77 | -1.81 |
| Shares, diluted (wtd. avg.) | — | — | 14.4M | 14.4M | 13.9M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $46.9M | $61.6M | $37.4M | $42.4M | $53.4M | $49.1M | $8.4M | $6.6M | $8.7M | $7.4M |
| Short-term investments | $290.1M | $314.1M | — | — | — | — | — | — | $3.0M | $13.8M |
| Total current assets | $343.9M | $376.9M | $1.0K | $42.7M | $54.4M | $50.0M | $8.5M | $6.8M | $12.3M | $21.4M |
| Property, plant and equipment | $288.0K | $162.0K | $10.0K | $25.0K | $48.0K | $21.0K | $10.0K | $24.0K | $42.0K | $66.0K |
| Total assets | $488.6M | $396.0M | $1.0K | $43.1M | $54.9M | $50.4M | $8.5M | $6.8M | $12.4M | $24.6M |
| Accounts payable | — | — | $362.0K | $334.0K | $1.1M | $1.8M | $418.0K | $230.0K | $622.0K | $1.2M |
| Total current liabilities | $15.4M | $13.0M | $637.0K | $1.1M | $3.5M | $3.5M | $926.0K | $793.0K | $2.1M | $2.4M |
| Total liabilities | $16.7M | $13.8M | $841.0K | $1.4M | $3.9M | $3.9M | $926.0K | $793.0K | $2.1M | $2.4M |
| Retained earnings | -$189.2M | -$83.7M | -$188.7M | -$183.4M | -$173.5M | -$154.2M | -$144.4M | -$138.9M | -$131.0M | -$112.5M |
| Total equity | $471.9M | $382.2M | $1.0K | $41.7M | $51.0M | $46.5M | $7.6M | $6.0M | $10.3M | $22.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$88.2M | — | -$5.0M | -$10.9M | -$18.8M | -$7.7M | -$4.8M | -$8.2M | -$17.5M | -$15.0M |
| Depreciation and amortisation | $83.0K | — | — | — | — | — | — | — | — | — |
| Stock-based compensation | $24.2M | — | $686.0K | $556.0K | $497.0K | $43.0K | $151.0K | $273.0K | $458.0K | $576.0K |
| Capital expenditure | $209.0K | — | $0 | $2.0K | $43.0K | $19.0K | $4.0K | $4.0K | $3.0K | $12.0K |
| Investing cash flow | -$96.7M | — | $0 | -$2.0K | -$43.0K | -$19.0K | -$4.0K | $3.0M | $12.9M | -$16.4M |
| Financing cash flow | $170.3M | — | $0 | $0 | $23.1M | $48.5M | $6.6M | $3.1M | $5.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-045159.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$16.4M | -$18.5M | -$7.9M | -$5.5M | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$83.7M | -$105.4M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |